A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology of Ipatasertib (GDC-0068) in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors
Latest Information Update: 17 Jan 2022
At a glance
- Drugs Ipatasertib (Primary) ; Docetaxel; Enzalutamide; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 22 Dec 2020 Status changed from active, no longer recruiting to completed.
- 03 Jun 2020 Planned End Date changed from 1 Jan 2020 to 1 Sep 2020.
- 03 Jun 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Sep 2020.